Celgene
Corporate Headquarters
86 Morris Avenue
Summit
New Jersey
07901
United States
Tel: 908-673-9000
Fax: 908-673-9001
Website: http://www.celgene.com/
About Celgene
At Celgene Corporation, we’re committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first. As a global leader in biotechnology and CAR T cell therapy, Celgene is a place where employees can make a real impact on the lives of patients with unmet medical needs in cancer and inflammatory diseases.
As we rapidly advance our next wave of innovative medicines, we announce the creation of a new global Clinical Development Organization to accelerate and optimize clinical development across our entire mid- to late-stage portfolio. Our commitments in this area will further establish the function as a center of excellence and enhance our strategic leadership in discovery, development and commercialization.
Recognized by Forbes in 2018 as a Top 10 World’s Best Employer and by Business Insider as the #3 Most Reputable Pharma Company in the World, Celgene offers a unique work environment where you can help build the business, while building your career in ways you may not have thought possible. We’re looking for innovative self-starters who want to improve the lives of patients worldwide. For more information, visit https://www.celgene.com/careers/.
CAR T cell therapy is a groundbreaking immunotherapy treatment that leverages a patient’s own immune system in fighting their cancer. Celgene is looking for dedicated people to join our team in this exciting area of cancer treatment.
989 articles with Celgene
-
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
-
Celgene Corporation to Webcast at Upcoming November and December 2018 Investor Events
11/2/2018
Celgene Corporation plans to present at two upcoming investor events where Celgene management will provide an overview of the Company.
-
Top 12 Life Science Companies Hiring Now
11/2/2018
Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now! -
Results from More Than 100 Abstracts Highlighting Celgene Pipeline Compounds and Therapies to Be Presented at the American Society of Hematology Annual Meeting (ASH)
11/1/2018
Presentations will cover a wide range of blood diseases including multiple myeloma, lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes and beta-thalassemia
-
Is the Biotech Bull Market Over?
10/31/2018
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016. -
Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).
-
BioSpace Movers and Shakers Oct. 29
10/29/2018
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more. -
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
-
Celgene Reports Third Quarter 2018 Operating and Financial Results
10/25/2018
Total net product sales of $3,890 million, increased 18% Y/Y
-
Celgene Corporation Chairman & CEO Mark J. Alles to Deliver Keynote Address at 2018 Washington State Life Science Summit
10/25/2018
Chairman & CEO Mark Alles of Celgene to deliver keynote speech at Washington State Life Science Summit
-
Celgene Corporation Chairman & CEO Mark J. Alles to Deliver Keynote Address at Washington State Life Science Summit
10/23/2018
Life Science Washington welcomes Mark J. Alles, Chairman and CEO of Celgene Corporation, as keynote speaker for its annual state summit gathering.
-
REVLIMID® (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma
10/23/2018
Celgene Corporation today announced results from an open-label phase II/III National Clinical Trials Network (NCTN) study.
-
Following several clinical disappointments and declining stock prices over the past year, Celgene tapped Alise Reicin as its new head of the company’s global clinical development unit, with a focus on mid- to late-stage therapeutics.
-
First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
10/22/2018
IMpassion130 reports first positive Phase III study results for a chemotherapy/immunotherapy (ABRAXANE plus atezolizumab) combination in first-line metastatic triple negative breast cancer (TNBC) patients
-
Celgene Corporation Announces Appointment of Dr. Alise Reicin to President, Global Clinical Development
10/22/2018
Dr. Alise Reicin will lead mid- to late-stage drug development across Celgene’s portfolio
-
Multiple biotech companies are scheduled to release their quarterly reports next week. BioSpace takes a quick look at some these companies and the announcements they have made through 3Q2018.
-
Refuge Biotechnologies Appoints Scott Smith to Board of Directors
10/15/2018
Former President and COO of Celgene to Help Guide Pipeline and Corporate Development Activities.
-
BioSpace Movers and Shakers for Oct. 15
10/15/2018
Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies. -
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
-
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.